Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRN4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,623
Award facts
- Contract value 100% obligated
- $25,622.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,622.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, on December 11, 2025. The delivery order, valued at the ceiling amount, is for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials, a specialty surgical anesthetic product, with an ultimate completion date of January 5, 2026. This award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order will be performed in Park Ridge, Illinois, and is funded by the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. The PPV-G GEN V contract represents a 30-month base period with three 30-month option periods and positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the Department of Defense's $30.3 billion pharmaceutical supply strategy. Under this overarching contract vehicle, the Defense Logistics Agency issues firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide, and DMS Pharmaceutical Group's established delivery order performance demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRN4?
SPE2DR26FCRN4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FCRN4 worth?
The government has obligated $25,623 on SPE2DR26FCRN4.
Is contract SPE2DR26FCRN4 an order under another contract?
Yes. SPE2DR26FCRN4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRN4 competed?
The extent of competition for SPE2DR26FCRN4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award